Latest research on Selzentry

Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.

Latest findings

MVC (Selzentry) was generously donated by Pfizer. [source, 2015]
Examples of drugs developed using such strategy include Pfizer’s Selzentry (Maraviroc) used for treatment of HIV Infection, SARcode’s Lifitegrast ophthalmic solution and Roche's RG7112 (a potent and selective member of the Nutlin family of inhibitors of p53-MDM2 binding used in treatment of solid tumors) (10). [source, 2015]
To the best of our knowledge, only two entry inhibitors have been approved by the Food and Drug Administration (FDA): enfuvirtide (T20), a fusion inhibitor, and Selzentry (maraviroc), a CCR5 antagonist. [source, 2013]
Several HIV-1 entry inhibitors including the fusion inhibitor T20 (Enfuvirtide, Fuzeon) and the coreceptor CCR5 antagonist Maraviroc (Selzentry) have also been approved by the US FDA and are used especially in those patients who fail to respond to HAART [1]. [source, 2013]
The CCR5 inhibitor maraviroc (Selzentry, MVC) and Nucleoside Reverse Transcriptase Inhibitor (NRTI) 3′-azido-2′, 3′-dideoxythymidine (AZT, used as a control drug) were obtained from NIH AIDS Research and Reference Reagent Program. [source, 2013]
aDrugs with sales above $100 million in 2010: Atripla ($2927 million), Truvada ($2746 million), Reyataz ($1479 million), Kaletra ($1255 million), Isentress ($1090 million), Prezista ($888 million), Epzicom ($858 million), Combivir ($561 million), Norvir ($344 million), Sustiva ($315 million), Viramune ($295 million), Intelence ($243 million), Trizivir ($223 million), Crixivan ($206 million), Epivir ($178 million), Ziagen ($159 million), Selzentry ($124 million), Viracept ($112 million); values from EvaluatePharma [23]. [source, 2013]
The enormous potential of HIV-1 to mutate [56], its ability to establish long-lasting viral reservoirs that are currently impossible to completely eradicate even with the highly active anti-retroviral therapy (HAART) [57], along with the emergence of resistant strains to the CCR5 antagonist maraviroc (Selzentry) (reviewed in [58]) and/or the fusion inhibitor T-20 (Enfuvirtide) [59], emphasize the importance of developing new and effective therapies to suppress virus entry. [source, 2012]
Maraviroc (MVC) (Celsentri) was from Pfizer, Inc. (New York, NY, USA). [source, 2011]
Clinical formulation of Maraviroc in a 150 mg tablet form ((Selzentry, Pfizer Labs) was ground and freshly dissolved in phosphate-buffered saline, sterile-filtered and adjusted to a final concentration of 4 mg/mL (7.8 mM). [source, 2011]